148 related articles for article (PubMed ID: 6617726)
1. Tizanidine--initial pharmacokinetic studies in patients with spasticity.
Heazlewood V; Symoniw P; Maruff P; Eadie MJ
Eur J Clin Pharmacol; 1983; 25(1):65-7. PubMed ID: 6617726
[TBL] [Abstract][Full Text] [Related]
2. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
[TBL] [Abstract][Full Text] [Related]
3. An approach to switching patients from baclofen to tizanidine.
Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
5. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
6. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
7. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
[TBL] [Abstract][Full Text] [Related]
8. Role of tizanidine in the treatment of spasticity.
Neurology; 1994 Nov; 44(11 Suppl 9):S1-80. PubMed ID: 7970005
[No Abstract] [Full Text] [Related]
9. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
10. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
11. Update on tizanidine for muscle spasticity and emerging indications.
Malanga G; Reiter RD; Garay E
Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
[TBL] [Abstract][Full Text] [Related]
12. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
13. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Vakhapova V; Auriel E; Karni A
Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
[TBL] [Abstract][Full Text] [Related]
14. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
15. Modified release tizanidine: a review.
Hutchinson DR
J Int Med Res; 1989; 17(6):565-73. PubMed ID: 2697626
[TBL] [Abstract][Full Text] [Related]
16. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
[TBL] [Abstract][Full Text] [Related]
18. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
Weynants L; Van Laere M
Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
[No Abstract] [Full Text] [Related]
19. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
